Compare ADMA Biologics Inc (ADMA) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Schwab US Dividend Equity ETF — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Schwab US Dividend Equity ETF trades at $32.39. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SCHD | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $32.83 |
52-Week Low | $7.60 | $26.38 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
SCHD trades at $32.24, down 0.46% today, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's dividend strategy is gaining attention amid rising interest in income-focused investments, with recent articles highlighting its 3.29% yield and low 0.06% expense ratio. Support and resistance levels cluster around $32-$33, indicating potential consolidation near current levels.
SCHD offers exposure to quality dividend-paying US stocks but faces mixed sentiment with some analysts citing underperformance versus broader markets. The fund's defensive positioning provides income stability, though total return comparisons with growth-oriented ETFs remain a key consideration for investors seeking balanced portfolio allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
